Related Experiment Video
Updated: Aug 30, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
Published on: May 17, 2019
[Anticytosine therapy for primary myelodysplastic syndrome]
K M Abdulkadyrov1, S V Gritsaev, S S Bessmel'tsev
1Russian Research Institute of Hematology and Transfusiology, Ministry of Health of the RF, St. Peterburg.
Abstract:
A pilot study of anticytocine therapy (PCD) was carried out in 9 patients with primary myelodysplastic syndrome (MDS). After 12 weeks, 2 patients (22%) showed hematological response cutting down the need for washed-out erythrocyte transfusions by half or more. MDS progression at different stages was reported in 4; transformation to acute myeloleukemia--2. PCD treatment is indicated in MDS patients, aged over 65, with a less than 10% blast level of the bone marrow, and without any risks of tumor progression.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Inhibitors of Viral Protein Synthesis